This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

approved Eylea biosimilars. These include the following: Yesafili (aflibercept-jbvf) Opuviz (aflibercept-yszy) Pavblu (aflibercept-ayyh) Ahzantive (aflibercept-mrbb) Enzeevu (aflibercept-abzv) ...

In 2024, the FDA approved biosimilar versions of Eylea, including the brand names Ahzantive, Enzeevu, Pavblu, Opuviz, and Yesafili. Anti-VEGF Treatments in the Pipeline In addition to injections, ...

The first biosimilars approved in the eye space were the ranibizumab biosimilars Byooviz (Samsung Bioepis and Biogen) and Cimerli (Coherus Biosciences), approved September 2021 and August 2022 ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of Regeneron's Eylea (aflibercept). Biocon ...

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). The ...

Two additional biosimilars that reference Eylea were approved in August 2024: Sandoz’s Enzeevu (aflibercept-abzv) and Amgen’s Pavblu (aflibercept-ayyh). Pavblu has already launched, despite ongoing ...

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD). Enzeevu ...

Formycon's biosimilar candidate to Eylea in Europe and in Israel, the company said Monday. This partnership combines Teva’s (TEVA) commercial experience in biosimilars and its extensive ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful ...

Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea ®1 (Aflibercept), ...